Wave Life Sciences announced positive interim Phase 1 data from the INLIGHT trial of WVE-007, showing placebo-adjusted reductions in visceral fat (-14%; p<0.01) and waist circumference (-5.8 cm) at six months after a single 240 mg dose, with muscle preservation. The company plans to initiate the Phase 2a multidose portion in individuals with BMI 35-50 kg/m² in Q2 2026.
Key takeaways
Single 240 mg dose of WVE-007 achieved -14% placebo-adjusted visceral fat reduction (p<0.01) at 6 months
Placebo-adjusted waist circumference reduction of -5.8 cm at 6 months
Preserved lean muscle mass with >500g loss only in placebo arm
Phase 2a multidose study (BMI 35-50 kg/m², comorbidities) to initiate Q2 2026
Additional Phase 1 data from 600 mg SAD cohort expected in 2026
Investor conference call held March 26, 2026 at 8:30 a.m. ET